Intersect ENT, Inc. (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $29.00, for a total transaction of $372,157.00. Following the sale, the chief financial officer now owns 27,833 shares in the company, valued at approximately $807,157. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Intersect ENT, Inc. (NASDAQ XENT) traded down 2.09% during trading on Thursday, hitting $30.50. 161,127 shares of the stock traded hands. The company’s 50 day moving average price is $28.68 and its 200-day moving average price is $21.49. Intersect ENT, Inc. has a 52-week low of $7.65 and a 52-week high of $31.90. The stock’s market cap is $890.26 million.
Intersect ENT (NASDAQ:XENT) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.11. The company had revenue of $24 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The firm’s quarterly revenue was up 24.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.21) EPS. Equities research analysts forecast that Intersect ENT, Inc. will post ($0.61) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Intersect ENT, Inc. (XENT) CFO Jeryl L. Hilleman Sells 12,833 Shares” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/17/jeryl-l-hilleman-sells-12833-shares-of-intersect-ent-inc-xent-stock-updated.html.
Several research firms recently commented on XENT. TheStreet upgraded shares of Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Canaccord Genuity restated a “buy” rating and set a $32.00 price target on shares of Intersect ENT in a research report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price objective on shares of Intersect ENT and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, Northland Securities reaffirmed a “hold” rating and set a $25.00 price objective on shares of Intersect ENT in a report on Wednesday, August 2nd. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Intersect ENT presently has an average rating of “Buy” and a consensus price target of $23.13.
Several hedge funds and other institutional investors have recently made changes to their positions in XENT. Dynamic Technology Lab Private Ltd bought a new position in shares of Intersect ENT during the second quarter valued at $297,000. Verition Fund Management LLC bought a new position in shares of Intersect ENT during the second quarter valued at $331,000. Moors & Cabot Inc. bought a new position in shares of Intersect ENT during the second quarter valued at $205,000. Cubist Systematic Strategies LLC bought a new position in shares of Intersect ENT during the second quarter valued at $229,000. Finally, State Street Corp raised its position in shares of Intersect ENT by 33.6% in the second quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock valued at $15,437,000 after buying an additional 138,968 shares during the last quarter. Institutional investors and hedge funds own 72.78% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
